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Introduction
Asthma is the most common chronic disease of South 
African children, affecting 10-20% of the population. It is 
sometimes difficult to diagnose. Where uncertainty exists, 
it may be more beneficial to treat the child as asthmatic, 
and then wean him or her off the medication later once 
it is under control, than neglect to administer the correct 
therapy to a true asthmatic. The treatment of asthma 
is often problematic, not because of lack of access to 
appropriate medication, but because of the central role 
played by additional factors, such as patient adherence and 
administration of medication technique.
It is always necessary to treat the child as an individual, but 
some measures apply in all cases. It is important to allay 
anxiety about the diagnosis. This is best done by carefully 
explaining the nature and causes of asthma, what to do 
if an attack occurs, why medicines are prescribed, and 
how they are given. Patients must be able to understand 
the difference between controller and reliever therapy. The 
importance of regularly using controller medication needs 
to be emphasised.
Time spent on the initial explanation and educating the 
parents and the child is always well rewarded by the 
response to treatment. Regular follow-up of these children, 
preferably by the same doctor, is very important. 
Environmental measures
It is insufficient to rely on medication alone to control the 
child’s symptoms. Parents who smoke should be advised 
to stop smoking altogether. It is not sufficient for parents 
to avoid smoking in the presence of their child. Chemicals 
and odours are transferred to children on the clothes of their 
parents, and smokers have increased carriage of respiratory 
pathogens, and may infect their own children. 
A typical history of symptoms at particular times of day 
(night-time for dust mite-sensitive patients), seasonally 
(grass or tree allergic patients), or upon exposure to 
allergenic triggers (e.g. pets and freshly mown lawn), along 
with appropriate testing for allergic sensitisation, will identify 
the triggers of an individual’s asthma. House dust mite-
allergic patients should prepare a dust-free environment in 
the child’s bedroom by changing furnishings and covering 
bedding with house dust mite impermeable coverings.
Drug treatment
Bronchodilators or “relievers”
These include short-acting β2-agonists, salbutamol and 
fenoterol. The long-acting β2-agonists, salmeterol and 
formoterol, should never be used as monotherapy, and 
are used as controller medication, despite their maximal 
effect being bronchodilation. Other bronchodilators that 
can be used are the anti cholinergic, ipratropium, and 
the theophyllines. Theophyllines are inexpensive oral 
bronchodilators, but have fallen out of favour because 
of their unpleasant side-effects, and the need to monitor 
therapeutic levels. All patients are prescribed a reliever 
medication to use as required for exacerbations. An 
increased frequency of use of reliever medication reflects 
poor control, and is an indication that regular controller 
therapy needs to be increased.
Anti-inflammatory drugs or “controllers”
Controller therapy is recommended for all patients with 
persistent asthma. Corticosteroids are the most effective 
controller therapy for asthma, and are usually administered 
by inhalation. The use of inhaled corticosteroids has 
significantly reduced admissions to hospital and deaths in 
children with episodes of acute severe asthma. Leukotriene 
receptor antagonists, e.g. montelukast, also have anti-
inflammatory effects via different pathways to inhaled 
corticosteroids (ICS). Long acting β2-agonists have weak 
anti-inflammatory effects, but are synergistic with inhaled 
corticosteroids. They are never used as monotherapy, 
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only as co-therapy with inhaled corticosteroids, and only 
in children older than five years of age. Combinations of 
inhaled corticosteroids and long-acting β2-agonists are 
now available which simplify the administration of regular 
anti-inflammatory therapy in children with asthma. 
Drug administration
Inhalation
This route delivers the drug directly to the airways, allowing 
for a smaller dose than that of the oral drug and reduces 
side-effects.
Metered dose inhalers
Metered dose inhalers (MDIs) are small aerosol devices. 
They are an effective and convenient way of administering 
many asthma drugs. A spacer device is essential for young 
children who would have difficulty using the MDI without 
it. Spacers increase drug deposition in the lungs, and also 
reduce local adverse effects from inhaled corticosteroids. 
As commercially produced spacers are often unavailable 
or unaffordable in many parts of this country, home-made 
spacer devices using a 500 ml plastic cold-drink bottle are 
a very useful and effective alternative (Figure 1). The plastic 
bottles can be modified to function as a spacer by melting 
a hole in the base of the bottle to fit the MDI. This is done 
by heating a wire mould of the same shape and size as the 
mouthpiece of the MDI in an open flame, and applying it 
to the centre of the base of the bottle. The mouthpiece of 
the MDI is inserted immediately after removal of the mould 
while still warm, so creating a tight fit. The spacer should 
be washed in detergent and air-dried or primed with 10-15 
puffs of the MDI aerosol prior to use, to reduce electrostatic 
charges. For young children and infants who are unable to 
hold a bottle in their mouths, a face mask can be attached 
to the neck of the bottle. 
Dry-powder inhalers
Virtually all forms of inhaled asthma medication are available 
in dry powder inhaler form. These inhalers are simple 
devices that can be successfully used in some children from 
about six years of age.
Nebulisers
Solutions for nebulisation are available for use in acute 
asthma attacks. However, an equivalent or superior effect 
can be achieved with 10 doses of salbutamol 100 ug via 
a metered dose inhaler and spacer (1 mg) as one dose of 
salbutamol via a nebuliser (2.5 mg). Solutions administered 
by a nebuliser are driven by oxygen in hospitals or clinics. 
However, home nebulisers are electrically driven and do not 
provide oxygen, which is a serious limitation to their use, 
and they are usually not recommended. Home nebulisers 
may give patients a false sense of security, and parents 
should be aware that they must seek immediate medical 
care should their child’s acute asthma episode not respond 
to a single nebulisation of bronchodilator medication.
Oral asthma medication
The oral route is used when administration by inhalation is 
not possible. Systemic side-effects occur more frequently 
when asthma medications are given orally. Oral preparations 
that can be taken include β2-agonists, corticosteroids, 
and theophyllines. The leukotriene receptor antagonist, 
montelukast, has few, if any side-effects, and is available 
in sprinkle, chewable, and tablet forms, making for easy 
administration in infants and children of all ages.
Assessment of severity is used as a starting point to assign 
a child to a particular treatment group. Intermittent asthma 
requires only reliever therapy and environmental control, 
whereas persistent asthma requires regular controller 
therapy (Table I and Table II). Patients with mild-persistent 
asthma are commenced on Level 1 therapy, moderate-
persistent on Level 2 therapy, and severe-persistent on 
Level 3 therapy.
Follow-up and assessment of control
Aims of the treatment are to:
•	 Enable the child to lead a normal life.
•	 Grow and develop normally.
•	 Attend school regularly.
•	 Sleep well at night.
•	 Participate in sport and activities.
•	 Stay out of hospital.
Re-evaluation after commencement of regular therapy 
is necessary within six weeks. Persistence of symptoms, 
particularly nocturnal cough and exercise-induced 
symptoms, may indicate inadequate control in treated 
asthmatics. Figure 1: Homemade plastic bottle spacer
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Assessment of control includes asking routine follow-up 
questions:
•	 In the last week, how often have you experienced asthma 
symptoms?
•	 In the last week, how often have you been woken at night 
because of asthma symptoms?
•	 In the last week, how often have asthma symptoms 
limited your ability to be active?
•	 In the last week, how many puffs of reliever medicine 
have you used?
•	 In the last month, have you missed any days of school/
work because of asthma?
Similar to the assessment of initial severity, assessment 
of control depends on the frequency of symptoms and 
measures of lung function, but the need for reliever therapy 
also indicates poor control (Table III). A patient must be 
assigned to the most severe grade in which any feature 
occurs. Where asthma is uncontrolled, initial concerns 
must be with adherence and medication administration 
technique, or the presence of unaddressed triggers or co-
morbid conditions. If this is thought to be the reason for 
poor control, medication should be left unchanged, but 
adherence and technique improved through education and 
repeated demonstration. 
Where asthma is uncontrolled despite good adherence and 
technique, treatment may be increased by one step. If the 
asthma is under control for at least three months, consider 
reducing the therapy. Apply extra cautious when reducing 
therapy (even if good control is achieved) in children who 
have experienced previous life-threatening asthma, or who 
have concomitant severe food allergies /anaphylaxis due to 
the increased risks of severe asthma in these children.
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Normal < 80% < 80%
a = Applicable to children older than five years, b = peak expiratory flow rate/forced expiratory 
volume in one second
Referral
Children with intermittent asthma and those controlled on 
Level 1 therapy should be treated in primary care. Children 
on Level 3 treatment and those under the age of two should 
be considered for assessment by a paediatric allergist or 
pulmonologist. Other indications for referral are when the 
diagnosis is in doubt, multiple severe concomitant allergic 
diseases exist, the asthma is difficult to control, or where 
a patient experiences life-threatening asthma, or has 
frequent attacks, or requires regular oral steroids, or when 
immunotherapy is being considered. 
The National Asthma Education programme (www.asthma.
co.za) provides free patient and doctor educational 
materials, and runs an asthma certificate course to teach 
doctors and nurses how to assess asthma, and to educate 
patients about how to use their medication to achieve 
optimum asthma control. 
Table II: Low, medium and high inhaled corticosteroid doses in controller 
therapy in children
Drug




High daily dose 
(µg)
Beclomethasone 
dipropionate 100-200 200-400 > 400
Budesonide 100-200 200-400 > 400
Ciclesonide 80-160 160-320 > 320
Fluticasone 100-250 250-500 500
Table I: Controller therapy for persistent asthma in children 





































a = inhaled corticosteroid, b = leukotriene receptor antagonist, c = long-acting β2-agonist
